Dopamine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Dopamine: From Hypotensive Disorder to Postural Orthostatic Tachycardia Syndrome
One-Sentence Summary
Dopamine is a catecholamine vasopressor, originally used to treat hypotensive disorders. The TxGNN model predicts it may be effective for Postural Orthostatic Tachycardia Syndrome (POTS), but there are currently 0 clinical trials and 5 publications (none testing dopamine as a treatment) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypotensive disorder |
| Predicted New Indication | Postural orthostatic tachycardia syndrome |
| TxGNN Prediction Score | 88.0% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, dopamine is an endogenous catecholamine and a precursor of norepinephrine. It acts as a vasopressor on dopaminergic and adrenergic receptors, and its efficacy in hypotensive states is established.
POTS is an autonomic disorder involving catecholamine dysregulation and abnormal neurohumoral responses to standing. The literature supports a biological link, including catecholamine abnormalities and norepinephrine-transporter mutations in familial cases. This makes a connection to a catecholamine drug plausible at the model level.
However, the retrieved papers concern other agents (bupropion, DA-9701) or are descriptive. No study tests dopamine itself as a POTS treatment. Intravenous dopamine is also impractical for a chronic outpatient condition.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32606041 | 2020 | Cohort (single-center, other drug) | J Investig Med | Retrospective chart review of 47 POTS patients treated with bupropion (a norepinephrine and dopamine reuptake inhibitor); not dopamine itself |
| 41952405 | 2026 | RCT (pilot, other drug) | J Neurogastroenterol Motil | DA-9701, a prokinetic acting on 5-HT1A, 5-HT4 and D2 receptors, assessed for GI symptoms in POTS |
| 28522107 | 2017 | Observational | Auton Neurosci | Neurohumoral and haemodynamic responses to prolonged head-up tilt in high vs normal standing norepinephrine POTS |
| 16601453 | 2006 | Case series/Genetic | Curr Opin Cardiol | Familial orthostatic tachycardia; norepinephrine transporter mutation prompted genetic analysis |
| 12102462 | 2002 | Review | Clin Auton Res | Catecholamine abnormalities, including dopamine beta-hydroxylase deficiency causing severe orthostatic hypotension |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11216P | TROPIN 200 INJECTION 200 mg/5 ml | Injection | Not stated in the data compiled for this report |
Safety Considerations
- Contraindications flagged by the knowledge graph (not label text): adrenal gland pheochromocytoma, phaeochromocytoma, sympathetic paraganglioma, adrenal gland cancer, heart cancer, duodenum cancer, small intestine cancer, acidosis disorder, and acquired lactic acidosis.
- Drug Interactions: 86 interactions were identified. The ones listed are all Moderate-level, and most are antidiabetic agents, including:
- Sulfonylureas: chlorpropamide, acetohexamide, glimepiride, glipizide, glyburide
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
- GLP-1 agonists and DPP-4 inhibitors: albiglutide, dulaglutide, exenatide, alogliptin
- Insulins and acarbose
- Diethylpropion
Package insert warnings and contraindications for the Singapore product were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output and an indirect biological link. No trial or paper tests dopamine for POTS, and intravenous dosing is poorly suited to a chronic outpatient condition. Other predicted indications are weaker still: multiple system atrophy, gastroduodenitis and peptic ulcer disease have only indirect L4 evidence, and the rest have none or only irrelevant literature.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data for dopamine
- Direct clinical evidence of dopamine in POTS, plus an assessment of whether a non-intravenous route is feasible
- A review of knowledge-graph contraindications against the intended patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.